Consolidation in the ASC sector has moved beyond speculation into measurable market dominance. Recent industry research shows that private equity, national operators, and hospital systems now control a sizable and growing portion of the ambulatory surgery landscape.

Out of an estimated approximately 12,000 ASCs in the U.S. (including 6,398 Medicare-certified facilities), a large and increasing share is affiliated with major consolidators, including SCA Health (with over 370 centers and more than 1 million procedures annually) under Optum, United Surgical Partners International, and other national platforms.

Market projections reveal that the U.S. ASC industry was valued at about $45.6 billion in 2024 and is anticipated to grow by more than 20 % through 2029, with outpatient surgical volumes expected to approach 110 million annual cases by 2033.

Recent private equity–backed consolidation deals and sector expansions have translated into measurable pricing dynamics: some acquired ASCs have reported per-case price increases of nearly 50 % within a few years post-acquisition, even without substantial changes in patient complexity or service improvements.

For surgeon-owners, the strategic calculus has shifted: the decision is rarely “if” to engage with capital partners but rather when and how to partner, balancing governance, valuation multiples, and long-term operational autonomy.